Repurposing chlorpromazine as add-on in the adjuvant phase of first-line
glioblastoma therapeutic protocol in patients carrying hypo-/un-methylated
MGMT **gene promoter: RACTAC, a Phase II multicenter single-arm clinical trial**

Andrea Pace[1], Giuseppe Lombardi[2], Veronica Villani[1], Dario Benincasa[1], Claudia Abbruzzese[1],
Ilaria Cestonaro[2], Martina Corrà[2], Giulia Cerretti[2], Mario Caccese[2], Antonio Silvani[3], Paola
Gaviani[3], Diana Giannarelli[4] and Marco G. Paggi[1$]

[1] IRCCS - Regina Elena National Cancer Institute, Rome, Italy
[2] Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
[3] IRCCS Besta Neurological Institute, Milan, Italy
[4] Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy

[$]**Corresponding author:**
Marco G. Paggi, MD, PhD
IRCCS - Regina Elena National Cancer Institute
Via Elio Chianesi 53, 00144 Rome, Italy
Tel.: +39-06-5266.2550; Email: marco.paggi@ifo.it
16

Abstract

Background. Glioblastoma (GBM) is a devastating brain tumor with poor prognosis,
characterized by rapid growth and invasion into surrounding brain tissue. It is a hard-to-treat
cancer and represents an unmet medical need. In recent years, there has been a growing
interest in developing novel approaches to improve the outcomes of GBM patients; among
these, drug repurposing. Our preclinical studies identified the antipsychotic chlorpromazine
(CPZ) as an important modulator of signal transduction and energy metabolism in GBM cells,
so we embarked on a Phase II clinical trial in which CPZ has been added to the standard
disease treatment.
Methods. With these assumptions, we started a multicenter phase II clinical trial on newly
diagnosed GBM patients carrying hypo-/un-methylated *MGMT* gene promoter by adding
CPZ to temozolomide (TMZ) in the adjuvant phase of the standard first-line therapeutic
protocol RACTAC schedule. Primary endpoints: Progression-Free Survival (PFS) and
Combination treatment toxicity. Secondary endpoints: Overall Survival (OS) and Quality of
Life (QoL)
Results. The RACTAC schedule showed an overall clinical benefit in GBM patients carrying
hypo-/un-methylated *MGMT* gene promoter. When compared with historical cohorts, these
patients displayed longer PFS, with toxicity described as a dose-dependent sedation and liver
toxicity, both expected. One case of severe liver toxicity has been reported. OS and QoL are
still under evaluation.
Conclusions. This clinical trial confirms the anticancer properties of CPZ, as described in
several preclinical studies. In addition, the RACTAC study can be considered at least as a
proof-of-concept in demonstrating the effectiveness of interfering with the well-described
oncogenic monoamine signaling between neurons and GBM.
41
42 **Keywords**: Glioblastoma; Drug repurposing; Chlorpromazine; Phase II multicenter single-arm
43 clinical trial.
44

Introduction

Glioblastoma (GBM) is the most frequent and severe brain tumor, characterized by poor response to treatment and an almost certainty of relapse and thus by bad prognosis. First-line GBM treatment, regardless its molecular classification (1), consists in maximal surgical resection followed by radiotherapy with concomitant temozolomide (TMZ) treatment, followed by adjuvant TMZ administration. This scheme, although considered the best one available, is associated with a median overall survival of 14.6 months and a 5-year survival <5% (2), a clinical course that clearly denotes an unmet medical need.

GBM peculiar biological characteristics confer it high invasive and infiltrative properties (3), mainly connected with a distinctive cellular heterogeneity, a prerequisite for a swift adaptation under therapeutic pressure (4-7). A key role in GBM therapeutic resistance is played by its ability to recover from genetic damages induced by radiotherapy and TMZ, due to an efficient DNA repair system, especially in tumors characterized by hypo- or un-methylated O6-methylguanine methyltransferase (*MGMT*) gene promoter (8). Of note, GBM is among the few tumors in which a mono-pharmacological treatment is still in use, in contrast with most therapeutic approaches in oncology and with its intratumor heterogeneity.

An interesting characteristic of GBM cells is their responsiveness to neurotransmitters, as monoamines, physiologically involved in neuron-neuron crosstalk (9, 10). The recent discovery of a synaptic GBM-neuron connectivity confirms that neuron-secreted mediators are taken up by GBM cells and utilized as oncogenic stimuli (11). These findings paved the way for considering the addition of selected neuroleptic drugs as potentially effective in GBM treatment (12). With these assumptions, we chose to assay the effects of one of the

progenitors of neuroleptic medications, i.e., the antipsychotic and anti-dopaminergic drug

chlorpromazine (CPZ), in use since almost 70 years for the therapy of several psychiatric

disorders, a compound listed in the 2021 WHO Model List of Essential Medicines (current

version) (13). Our *in vitro* assays on established and primary human GBM cells allowed us to

confirm and define the role of this drug in hindering GBM cell growth by acting at different

levels, e.g., induction of cytotoxic autophagy, nuclear catastrophe, oxidative stress, in a

context where non-cancer neuroepithelial cells appeared safeguarded (14, 15). Our further

data (unpublished) also defined the role of CPZ in hindering GBM bioenergetics and anabolic

pathways.

These results paved the way for repurposing CPZ as an add-on drug in GBM therapy. To this

end, we planned the RACTAC (Repurposing the Antipsychotic drug Chlorpromazine as a

Therapeutic Agent in the Combined treatment of newly diagnosed glioblastoma) Phase II

multicenter single-arm protocol, in which CPZ has been added to the adjuvant TMZ therapy

in the first-line therapeutic approach towards GBM patients whose tumor was characterized

by a hypo-/un-methylated *MGMT* gene promoter, i.e., those characterized by resistance to

TMZ and overall worse prognosis.

The aim of this report is to describe the intervention, design, endpoints, power calculations

and clinical results of this study.

Materials and Methods

Study design

The experimental procedure involves the combination of CPZ with standard treatment with TMZ in the adjuvant phase of the Stupp protocol (2). CPZ has been administered orally at a dose of 25-50 mg/day, day 1-28 of every cycle of the adjuvant treatment with TMZ (**Figure 1**). A complete protocol description is available at

https://clinicaltrials.gov/ct2/show/NCT04224441

Participants, intervention and outcomes

Patients with confirmed histological diagnosis of GBM carrying a hypo-/un-methylated *MGMT* gene promoter have been recruited. The experimental treatment involves the association of CPZ with the standard TMZ chemotherapeutic regimen during the Stupp adjuvant phase. Power calculation indicates to recruit ≥41 patients.

PRIMARY ENDPOINTS: Progression-Free Survival (PFS); Combination treatment toxicity. PFS is defined as the time from the beginning of radiotherapy to the earliest documented date of disease progression, based on Response Assessment in Neuro-Oncology (RANO) criteria (16), as determined by the investigator, or death due to any cause. Evaluating a meta-analysis performed on 91 GBM trials, the choice of PFS as an endpoint can be considered appropriate as surrogate endpoint for earlier evaluation. The 6-mosPFS is highly correlated with 1 year OS and median OS (17).

SECONDARY ENDPOINTS: Overall Survival (OS); Quality of Life (QoL) will be assessed by means of the EORTC QLA C30+BM20 questionnaire at baseline and every 3 cycles.

Data collection, management and analysis

Inclusion criteria:

1. Patients with newly diagnosed GBM carrying a non-methylated *MGMT* gene, with

confirmed diagnosis after surgical excision or biopsy, and after the combined radio-

chemotherapy treatment.

2. Age between 18 and 70 years; Karnofsky Performance Status (KPS) above 70; normal

liver and kidney function.

3. Patients who have signed informed consent before entering the study.

Monitoring

Patients were monitored in accordance with the usual rules for GBM patients (2).

Ethical considerations

This Phase II clinical trial has been approved by our Institutional Ethics Committee (Comitato

Etico Centrale IRCCS - Sezione IFO-Fondazione Bietti, Rome, Italy) on September 6, 2019

(EudraCT # 2019-001988-75; ClinicalTrials.gov Identifier: NCT04224441).

Trial status

The recruitment lasted 30 mos and ended on June 30, 2022, after reaching the number of 52

evaluable patients. Follow-up ended on December 31, 2022.

Drug

CPZ was purchased, as "Largactil", from Teofarma S.R.L., Valle Salimbene (PV), Italy, as 25

mg tablets.

Statistical analysis

The primary objective of the study was to evaluate the proportion of patients free from

progression after 6 months (PFS-6). Considering as unacceptable a percentage of PFS-6 (P0)

equal or less than 35% and a desirable PFS-6 of 55% (P1), a minimum of 41 patients will be

needed to guarantee a power of 80% at a significance level of 5%, according to A'Hern (18).

If at least 20 patients are progression-free after 6 mos, the treatment will be considered

sufficiently active. Associations between categorical variables have been evaluated with the

Chi Square or Fisher's exact test. In the case of quantitative variables, comparisons will be

evaluated by means of Student's *t* test or Mann-Whitney's non-parametric U test.

Comparisons at various times will be evaluated using ANOVA for repeated measurements or

Friedman tests. All survivals have been calculated by the Kaplan-Meier method.

PFS is calculated from Day 1 of the radiotherapeutic treatment.

Results

Key findings

Patients carrying a GBM with unmethylated *MGMT* promoter gene, i.e., those with worse

prognosis and characterized by an overall resistance toward radio- and chemotherapy,

showed an overall good tolerance from the application of the RACTAC schedule.

Median age at enrollment was 59 ± 11.7 (SD) years; 57% of the participants were male, and

median initial KPS was 90.

Treatment response

Out of the 52 evaluated patients, 21 received 6 cycles of chemotherapy plus CPZ (42%)

(mean number of cycles administered = 4.5). Adherence to the study medication was high,

with only 4 patients interrupting early CPZ assumption (3 cases) or reducing the dosage due

to sedation (1 case).

At the time of analysis, the median follow-up was 15 mos. Forty-four patients underwent

disease progression, with a median PFS of 7.3 mos (95% CI: 6.7-7.9) (**Figure 2**). Reference PSF

(historical median) is reported as 4.9 mos (19).

PFS at different times is reported in **Table 1**.

Adverse events

The RACTAC clinical experimentation has been correlated with the onset of an expected

dose-dependent sedation, especially at the beginning of the CPZ administration, and liver

toxicity (1 serious case), however expected for both CPZ and TMZ.

Discussion

Considering the plasticity of GBM and its ability to remodulate its cell population based on the selective pressure generated by therapies, we can state that this tumor cannot be defined as a "single-path disease", being therefore very unsatisfying to treat it by means of targeted therapies (20). On these premises, it appears reasonable to consider the opportunity to use "dirty drugs", i.e., drugs that are not too targeted, but are able to hit some generalized vulnerabilities of cancer cells.

CPZ is a well-known DRD2 antagonist and therefore has been successfully used in the treatment of psychiatric disorders (21). We intended to take advantage of its ability to interfere with synaptic neuromediators to turn off the pseudo-synaptic interplay between neurons and GBM, also considering a number of preclinical studies showing the ability of this drug to hinder GBM malignant features (22). In addition, during the course of the RACTAC clinical trial, we refined more accurately the effects of CPZ on GBM cells in preclinical settings, demonstrating the ability of this medication to interfere with GBM growth at multiple levels (14, 15). The RACTAC results reported here can be considered at least as a proof-of-concept in proving the effectiveness of interfering with the oncogenic monoamine signaling between neurons and GBM.

The spiraling costs of new cancer drugs and the long time it takes for them to reach the market require a profoundly different approach to keep life-saving therapies affordable for cancer patients. In such a context, repositioning for the treatment of GBM can be a relatively inexpensive, safe and rapidly implemented approach.

184   **Funding**: Work partially financed by Funds Ricerca Corrente 2018-2019, 2020-2021, 2022-
185   2023 from Italian Ministry of Health (MGP) and by the European Union – Next Generation
186   EU – PNRR M4C2 – Investment 1.3 via MUR (MGP).

187   **Conflict of Interest**: The authors declare no conflict of interest.

References:

1.   Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803-20.

2.   Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-96.

3.   Rao JS. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer. 2003;3(7):489-501.

4.   Lan X, Jorg DJ, Cavalli FMG, Richards LM, Nguyen LV, Vanner RJ, et al. Fate mapping of human glioblastoma reveals an invariant stem cell hierarchy. Nature. 2017;549(7671):227-32.

5.   Gimple RC, Bhargava S, Dixit D, Rich JN. Glioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancer. Genes Dev. 2019;33(11-12):591-609.

6.   Couturier CP, Ayyadhury S, Le PU, Nadaf J, Monlong J, Riva G, et al. Single-cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelopmental hierarchy. Nat Commun. 2020;11(1):3406.

7.   Hubert CG, Lathia JD. Seeing the GBM diversity spectrum. Nat Cancer. 2021;2(2):135-7.

8.   Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997-1003.

9.   Caragher SP, Hall RR, Ahsan R, Ahmed AU. Monoamines in glioblastoma: complex biology with therapeutic potential. Neuro Oncol. 2018;20(8):1014-25.

10.   Caragher SP, Shireman JM, Huang M, Miska J, Atashi F, Baisiwala S, et al. Activation of Dopamine Receptor 2 Prompts Transcriptomic and Metabolic Plasticity in Glioblastoma. J Neurosci. 2019;39(11):1982-93.

11.   Venkataramani V, Schneider M, Giordano FA, Kuner T, Wick W, Herrlinger U, et al. Disconnecting multicellular networks in brain tumours. Nat Rev Cancer. 2022.

12.   Persico M, Abbruzzese C, Matteoni S, Matarrese P, Campana AM, Villani V, et al. Tackling the

Behavior of Cancer Cells: Molecular Bases for Repurposing Antipsychotic Drugs in the Treatment of

Glioblastoma. Cells. 2022;11(2):263.

13.   World Health Organization Model List of Essential Medicines, 22nd List. Geneva: World

Health Organization; 2021.

14.   Matteoni S, Matarrese P, Ascione B, Buccarelli M, Ricci-Vitiani L, Pallini R, et al. Anticancer

Properties of the Antipsychotic Drug Chlorpromazine and Its Synergism With Temozolomide in

Restraining Human Glioblastoma Proliferation In Vitro. Front Oncol. 2021;11:635472.

15.   Matteoni S, Matarrese P, Ascione B, Ricci-Vitiani L, Pallini R, Villani V, et al. Chlorpromazine

induces cytotoxic autophagy in glioblastoma cells via endoplasmic reticulum stress and unfolded

protein response. J Exp Clin Cancer Res. 2021;40(1):347.

16.   Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated

response assessment criteria for high-grade gliomas: response assessment in neuro-oncology

working group. J Clin Oncol. 2010;28(11):1963-72.

17.   Han K, Ren M, Wick W, Abrey L, Das A, Jin J, et al. Progression-free survival as a surrogate

endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials. Neuro

Oncol. 2014;16(5):696-706.

18.   A'Hern RP. Sample size tables for exact single-stage phase II designs. Stat Med.

2001;20(6):859-66.

19.   Alnahhas I, Alsawas M, Rayi A, Palmer JD, Raval R, Ong S, et al. Characterizing benefit from

temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review

and meta-analysis. Neurooncol Adv. 2020;2(1):vdaa082.

20.   Le Rhun E, Preusser M, Roth P, Reardon DA, van den Bent M, Wen P, et al. Molecular

targeted therapy of glioblastoma. Cancer Treat Rev. 2019;80:101896.

21.   Horn AS, Snyder SH. Chlorpromazine and dopamine: conformational similarities that

correlate with the antischizophrenic activity of phenothiazine drugs. Proc Natl Acad Sci U S A.

1971;68(10):2325-8.

22.   Abbruzzese C, Matteoni S, Persico M, Villani V, Paggi MG. Repurposing chlorpromazine in the

treatment of glioblastoma multiforme: analysis of literature and forthcoming steps. J Exp Clin Cancer

Res. 2020;39(1):26.

245
246

Figure 1

Scheme of the daily addition of chlorpromazine (CPZ) during the adjuvant phase of the Stupp

protocol (weeks 1 to 24).

Figure 2

Kaplan-Meier curve describing the PFS trend in GBM patients carrying hypo/un-methylated
MGMT gene promoter treated according to the RACTAC protocol.

Table 1

Progression-free survival (PFS) in GBM patients carrying hypo/un-methylated *MGMT* gene
promoter treated according to the RACTAC protocol.

PFS at 6 mos	64.9%
PFS at 12 mos	24.5%
PFS at 18 mos	11.5%
PFS at 24 mos	11.5%